Atwood & Palmer Inc Neurocrine Biosciences Inc Call Options Transaction History
Atwood & Palmer Inc
- $1.43 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
656Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.57 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.12 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$540 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$333 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$280 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...